← Back to news

Markets

Goldman Sachs Hikes Insmed (INSM) Price Target to $112 Affirms Buy Rating

Y

Cardinal Health (CAH) Affirms Long-Term Growth Raises Outlook

Y

Tenet Healthcare Corp (THC) on the Spot over Medicare Fraud Allegations

Y

Morgan Stanley Hikes McKesson (MCK) Price Target on Earnings Growth Prospects

Y

IDEXX Laboratories (IDXX) Price Target Hiked to $580 at Leerink Partners

Y

Ascendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects

Y

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

Y

Cigna (CI) Unveils AI-Powered Tools to Enhance Healthcare Delivery

Y

Morgan Stanley Hikes Labcorp (LH) Holdings Price Target to $283 Affirms ‘Overweight’ Rating

Y

AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C

Y

UBS Affirms Neutral Rating on Baxter International (BAX)

Y

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics

Y

IAG: Earnings Jet To New Heights, Yet All-Time Highs Stay In The Hangar - Sell The Cycle-Peak

S

Tipping Points - How Will Markets Respond?

S

CoreWeave: Three Realistic Scenarios, Pick Yours

S

Nutrien: Not Attractive Enough To Justify Buying Yet

S

Berkshire Hathaway: Buffett's Out, Billions In Doubt

S

Conflict concerns weigh on indexes, bolster oil and US debt

Y

SoftBank raises $4.8 billion from T-Mobile share sale, term sheet shows

Y

Oil prices rise more than 4% as Iran-Israel conflict escalates

Y

Rob Arnott’s Firm Says the Time Is Finally Right for ‘Smart Beta’

Y

Boeing Could Avoid a Trial

Y

5 Safe Dividend Stocks Yielding Over 5% You Can Buy Without Hesitation Right Now for Passive Income

Y

2 Top Artificial Intelligence Stocks to Buy Right Now

Y